Decreases in local hormone biosynthesis and c-fos gene expression accompany differentiation of porcine preadipocytes.
To better understand possible autocrine or paracrine mechanisms involved in adipose tissue development, we have studied the biosynthesis of insulinlike growth factor I (IGF-I) and prostaglandin E2 (PGE2) by cultured porcine preadipocytes in response to factors known to modulate cell growth and differentiation. The expression of c-fos was also monitored because of the potential role of that proto-oncogene in coordination of growth and differentiation. Preadipocytes were grown to confluence and then maintained in one of three media treatments: a) standard medium supplemented with 10% fetal bovine serum (FBS), b) FBS supplemented with dexamethasone (Dex), c) FBS supplemented with dibutyryladenosine 3'-5'-cyclic monophosphate. Indirect measurements of growth indicated that cell proliferation did not differ due to media type. Histochemical and enzymatic measurements of adipocyte development revealed that differentiation occurred only in those cultures exposed to Dex. The increase in adipocyte differentiation in response to Dex was associated with a decrease in c-fos and actin RNA expression whereas the decrease in c-fos RNA expression in response to Dex was small (approximately 40%); immunocytochemical analysis indicated that induction of Fos protein occurred only in undifferentiated cells. Thus, the cells responsible for the decrease in c-fos RNA expression are possibly those signaled to differentiate into adipocytes. Expression of IGF-I RNA and secretion of IGF-I and PGE2 were also decreased in response to Dex treatment. These data provide the first demonstration that biosynthesis of IGF-I by preadipocytes can be modulated by a potent inducer of adipocyte differentiation. The combined results indicate that glucocorticoids may stimulate adipocyte differentiation by suppressing intracellular and putative intercellular mitogenic signals.
Department of Foods and Nutrition, University of Georgia, Athens 30602.
H R
HR
Gaskins
J W
JW
Kim
G J
GJ
Hausman
D000199:Actins / Q000235:genetics / Q000378:metabolism; D000273:Adipose Tissue / Q000166:cytology* / Q000378:metabolism / Q000502:physiology; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D003907:Dexamethasone / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D016760:Proto-Oncogene Proteins c-fos; D012313:RNA / Q000235:genetics / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000494:pharmacology; D013234:Stem Cells / Q000378:metabolism* / Q000502:physiology; D013552:Swine / Q000502:physiology*
D000199:Actins; D011518:Proto-Oncogene Proteins; D016760:Proto-Oncogene Proteins c-fos; D012710:Serum Albumin, Bovine; D012313:RNA; D003994:Bucladesine; D007334:Insulin-Like Growth Factor I; D003907:Dexamethasone; D015232:Dinoprostone